Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06309446
Other study ID # 381001BS
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 14, 2020
Est. completion date July 2, 2020

Study information

Verified date March 2024
Source Oystershell NV
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Test the wound healing properties of the product as well as the cooling effect and tolerability of a wound care gel.


Description:

The primary goal of the study is to assess the wound healing properties in the test fields, based on the level of re-epithelialization, and to assess the cooling properties in the test fields, immediately after the first application of the Medical Device. The secondary objective was to assess the local tolerability of the test fields after inducing the wounds. The cosmetic outcome was assessed by the investigator and by the subject after 31 days using a visual analog scale (VAS) and by the subjects on day 12 by filling a questionnaire on product performance and times to 100% healing, over 75% healing respectively were derived from the re-epithelization score.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date July 2, 2020
Est. primary completion date February 19, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women aged 18 years or older; - Healthy skin on the volar forearms; - The physical examination of the skin must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the clinical investigation; - Female volunteers of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices (IUDs), sexual abstinence or vasectomized partner; - Urine pregnancy test negative for all females; - Written informed consent obtained. Exclusion Criteria: - Acne, suntan, eczema, scars, excessive hair, acute skin infection or skin disease, hyper or hypopigmentation or tattoos in the test fields; - Dark-skinned persons (Fitzpatrick skin types IV-VI); - Pregnancy or planned pregnancy or nursing; - Symptoms of a clinically significant illness that may influence the outcome of the investigation in the 4 weeks before baseline and during the clinical investigation; - Participation in the treatment phase in another clinical investigation or clinical trial within the last 4 weeks prior to the baseline visit of this clinical investigation and during the conduct of this investigation; - Known hypersensitivity or known allergic reactions to components of the MD or the protective standard wound plaster used; - Treatment with systemic medications or medications acting locally in the test field areas which might counter or influence the investigation aim within 2 weeks before the baseline visit (e.g. antihistamines or glucocorticosteroids) and during the conduct of this investigation; - Subjects who have taken any anticoagulant medication, within 3 weeks prior to Day 1, or platelet aggregation inhibitors within 10 days prior to Day 1 or with a history of hemophilia or any other illness influencing the subject's coagulation system. - Subjects with diabetes mellitus or presence or history of psoriasis, atopic dermatitis, lichen ruber planus, impaired wound healing or keloid development; - Contraindications according to the package leaflet/instructions of use (Hansaplast Sensitive); - If in the opinion of the investigator or physician performing the initial examination the subject should not participate in the clinical investigation, e.g. due to probable noncompliance or inability to understand the investigation and adequately given informed consent; - Subjects not willing to adhere to trial restrictions, amongst others sauna, solarium are not allowed during the clinical investigation; - Close affiliation with the investigator (e.g. a close relative) or persons working at bioskin GmbH or subject is an employee of the sponsor; - Subject with a disposition to develop hypertrophic scarring, keloids or wound healing disorders; - Evidence of drug or alcohol abuse; - Subject is institutionalized because of legal or regulatory order.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Zoralan Wound
Topical application of approximately 0.2 g per test field (approx. 1.2 cm in diameter each) once daily during a 12-day treatment period (11 treatments).

Locations

Country Name City State
Germany Bioskin GmbH Hamburg

Sponsors (2)

Lead Sponsor Collaborator
Oystershell NV Bioskin GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wound healing efficacy (clinical) Clinical assessment of wound healing efficacy performed by investigator (6-point- reepithelialization score).
0 = 0% healing
= 1-25% re-epithelialization
= 26-50% re-epithelialization
= 51-75% re-epithelialization
= over 75% but not complete re-epithelialization
= 100% complete healing
Day 2, Day 6, Day 8, Day 10 & Day 12
Primary Wound healing efficacy (global) Global assessment of wound healing efficacy performed by investigator (5-point score).
0 = very good
= good
= acceptable
= poor
= very poor
Day 2, Day 6, Day 8, Day 10 & Day 12
Primary Cooling properties Subjective assessment of cooling properties performed by subject by completing a visual analogue scale on Day 1 immediately after application of the Medical Device (MD).The cooling effect in the two test fields will be assessed by the subject by means of a visual analogue scale (VAS) of 100 mm length, ranging from 0 (no cooling) to 100 (extremely cooling) on Day 1, 20 ±5 seconds after application of the MD (but prior to application of the protective wound plaster). Day 1
Secondary Local tolerability (clinical) Clinical assessment of local tolerability performed by investigator (5-point-erythemascore).
0 = no reaction
= slight uniform or spotty erythema or slight diffuse, partial or follicular erythema
= clear, sharply demarcated erythema
= severe erythema with infiltrate
= severe erythema with infiltrate and/or epidermal defect (blisters, blebs, erosions)
Day 2, Day 6, Day 8, Day 10 & Day 12
Secondary Local tolerability (global) Global assessment of local tolerability performed by subject and investigator (5-point score). 0 = very good
= good
= acceptable
= poor
= very poor
Day 2, Day 6, Day 8, Day 10 & Day 12
Secondary Signs of infection Assessment of signs of infection, considering the following parameters: erythema, pain, malodor, delayed wound healing, excessive exudate, and heat, by investigator (closed question: YES/NO). Day 2, Day 6, Day 8, Day 10 & Day 12
Secondary Time until 100% healing Time until 100% healing, defined as first day after wound induction with reepithelialization score of 5 (5 = 100% complete healing). Day 2, Day 6, Day 8, Day 10 & Day 12
Secondary Time until 75% healing Time until over 75% healing, defined as first day after wound induction with reepithelialization score of 4 or 5 (4 = over 75% but not complete re-epithelialization; 5 = 100% complete healing). Day 2, Day 6, Day 8, Day 10 & Day 12
Secondary Presence of crusts Presence of crusts (Yes/No) Day 2, Day 6, Day 8, Day 10 & Day 12
Secondary Questionnaire on product performance Questionnaire on product performance (filled by subjects) on Day 12 (12 closed questions) Day 12
Secondary Cosmetic outcome/acceptance The cosmetic outcome/acceptance will be assessed by the investigator and the subject by means of a visual analogue scale (VAS) of 100 mm length, ranging from 0 (poor) to 10 (excellent) on Day 31±2 for each of the two test fields. Day 31
Secondary Photographic documentation of the wound - visual of the wound to support previous outcomes. High-quality photographic documentation of the test sites on Days 1, 4, 6, 8, 10, 12 and 31 sufficient time (not earlier than 30 minutes but not later than 60 minutes) after removal of patches and product residues for any removal related erythema to subside. Day 1, Day 4, Day 6, Day 8, Day 10, Day 12 & Day 31
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03649308 - Negative Pressure Wound Therapy Compared to Traditional Care After Skin Grafting N/A
Recruiting NCT03674749 - The Effects of Meditation and Hyperbaric Oxygen Therapy on Chronic Wounds N/A
Completed NCT06464250 - The Effect of Bundle Approach on Foot Care Behaviors and Diabetic Wound Healing in Patients N/A
Withdrawn NCT03909503 - A Case Series Evaluating a Collagen Wound Dressing to Treat Wounds N/A
Completed NCT05297721 - Nurses' Level of Knowledge on Skin Tears: A Cross-Sectional Study
Recruiting NCT03386175 - Efficiency of Negative Pression Therapy With Instillation in the Debridement of Wound
Active, not recruiting NCT04701632 - Prevalence and Variables Associated With Depression in Subjects With Chronic Wounds Using PHQ-9 as a Screening Tool
Completed NCT05618496 - Multi-centre, Open-label, First-in-man Study With Epipad Used in Adult Patients N/A
Not yet recruiting NCT03640871 - HEAL Study: Healing Results, Efficacy and Acceptability of a New Contact Layer N/A
Completed NCT02399722 - Combination of a Polymeric Membrane Dressing Plus Negative Pressure Wound Therapy Against Negative Pressure Wound Therapy Alone N/A
Completed NCT04507724 - The Use of Biochemical Analyzes to Monitor the Development of Wounds
Recruiting NCT05556954 - Diabetic Foot Ulcers Microbiome and Pathogen Identification
Completed NCT03938584 - The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients N/A
Terminated NCT03723603 - An Evaluation of a Collagen Dressing to Treat Chronic, Stalled Lower-extremity Wounds N/A
Completed NCT03754426 - A Prospective, Pilot Evaluation of Device Equivalence
Recruiting NCT02643680 - Clinical Study of Biocellulose Wound Dressing Containing Silk Sericin and PHMB for STSG Donor Sites Phase 2
Recruiting NCT01913132 - PICO Above Incisions After Vascular Surgery N/A
Recruiting NCT01347489 - Cronic Pressure Wounds and Relation With Gender N/A
Recruiting NCT04621825 - Post Market Surveillance Study to Confirm Safety and Performance of Silicone PHMB Foam N/A
Withdrawn NCT03723577 - An Evaluation of a Fibrillar Collagen Dressing to Treat Chronic, Stalled Lower-extremity Wounds N/A